CN102727605A - Oral liquid for treating vital myocarditis - Google Patents
Oral liquid for treating vital myocarditis Download PDFInfo
- Publication number
- CN102727605A CN102727605A CN2012102473246A CN201210247324A CN102727605A CN 102727605 A CN102727605 A CN 102727605A CN 2012102473246 A CN2012102473246 A CN 2012102473246A CN 201210247324 A CN201210247324 A CN 201210247324A CN 102727605 A CN102727605 A CN 102727605A
- Authority
- CN
- China
- Prior art keywords
- grams
- oral liquid
- radix
- herba clinopodii
- viral myocarditis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses oral liquid for treating vital myocarditis. The oral liquid is prepared form the following medicinal raw materials: 25-35g of astragalus mongholicus, 25-35g of kuh-seng, 25-35g of coptis chinensis, 15-25g of ossa draconis, 15-25g of spina date seed, 15-25g of many-headed savory, 15-25g of honeysuckle, 5-15g of Chinese angelica, 5-15g of giant knot weed and 5-15g of toasted licorice root. The preparation method of the oral liquid comprises the following steps: collecting all the medicinal raw materials and mixing; decocting with water for 1-2h and filtering to obtain filtrate; decocting filter residues with water for 0.5-1.5h and filtering to obtain filtrate; mixing all the filtrates; concentrating till the relative density is 1.22-1.24 (50 DEG C) to obtain the oral liquid. When used for treating vital myocarditis, the oral liquid is orally taken twice a day on a full stomach, and a patient suffering from vital myocarditis can be healed generally after taking the oral liquid for 20-30 days. The oral liquid for treating vital myocarditis has the advantages of remarkable treatment effect, quick acting and no toxic or side effect, and the total effective rate of the oral liquid reaches 97.3%.
Description
Technical field
The present invention relates to a kind of oral liquid of treating viral myocarditis.
Background technology
((VMC) is the commonly encountered diseases and the frequently-occurring disease of cardiovascular system to viral myocarditis, also is one of dilated cardiomyopathy, heart failure and broken dead main inducing.At present, no matter in developed country still in developing country, myocarditic sickness rate increases than having significantly before 10 years, its main cause is due to the sickness rate of viral myocarditis increases in the infectious myocarditis.After viral infection is invaded cardiac muscle, can cause focal or diffusivity myocardium between matter property ooze out and myofibrosis cordis, necrosis.Serious arrhythmia, heart failure, cardiogenic shock even sudden death can appear in serious symptom diffusivity myocarditis; Also but protracted course of disease causes cardiac hypertrophy, and develops into dilated cardiomyopathy gradually.
The symptom of viral myocarditis possibly come across the symptom phase or the convalescent period of protopathy.The symptom phase as in protopathy occurs, and its performance can be covered by protopathy.Most of patients has symptoms such as heating, systemic pain, pharyngalgia, diarrhoea at premorbid, reflection general viral infection, but part patient protopathy mild symptoms is also arranged and little significantly, and carefully the side of questioning closely is noted, the myocarditis symptom is then relatively significantly.That myocarditis patient often tells is uncomfortable in chest, pareordia dull pain, cardiopalmus, weak, nauseating, dizzy.Clinically in the myocarditis of diagnosis, about 90% are chief complaint or head sees symptom with arrhythmia, and wherein small number of patients can take place to faint or this syndrome of Ah-therefrom.Only a few patient plays after being ill development rapidly, occur heart failure or heart source gonosome gram (Chen Haozhu. practical internal medicine. People's Health Publisher .1997 July the 10th edition).
Viral myocarditis is relevant with viral infection and immunity cardiac damage.From the viewpoint of modern medicine, Pathogenesis of Viral Myocarditis and pathophysiological process relate generally to following three aspects: one, the direct invasion and attack of virus cause myocardial cell to break, dissolve; Two, after virus causes the myocardial cell disintegrate, bring out the autoimmune inflammatory reaction; Three, bring out the body specific immune response behind the viral infection.This shows that viral myocarditis is main relevant with poisoning intrusion and immunoreation, seek antiviral drugs, adjusting immunity of organism and symptomatic treatment aspect so the starting point of treatment viral myocarditis just concentrates on.
Yet till now, Shang Weiyou is to the specific medicament of VMC.Two kinds of monomeric compounds that the viral myocarditis cell model had positive effect have only been reported in the world; They are respectively: Ribavirin and Win54954; But these two kinds of monomeric compounds all do not show the good curing effect on animal model, and visible exploitation has very large difficulty to the new drug of viral myocarditis.Scientists will concentrate on following four aspects to the drug research of viral myocarditis thus: the immunologic function of, regulating the viral myocarditis patient; Two, exploitation attenuated live vaccine; Three, seek the breach of gene therapy; Four, carry out symptomatic treatment to the change of cardiovascular system.
Chinese medicine is one of time-honored natural drug in the world, in the treatment of viral myocarditis, has certain advantage and characteristic.The viewpoint of motherland's traditional medicine thinks that viral myocarditis belongs to traditional Chinese medical science severe palpitation, the category that the thoracic obstruction etc. are sick.This cause of disease is deficiency of vital QI, stagnated in evil by pathogenic warmth calentura invasion and attack, poison again, in be contained in that the heart, blood fortune are smooth, become homeless foster, venation of consumption impairment of QI sun, the heart becomes silted up due to resistance, the turbid damp and hot retardance of expectorant.So the treatment viral myocarditis is main when controlling the heart with strengthening vital QI to eliminate pathogenic factors, takes into account other internal organs, be main with the beneficial motive, the sun that nourishes heart, pure and fresh allaying excitement.Yet aspect the traditional Chinese medicine of China, the very definite medicine of curative effect never, most of doctors are carrying out the flavour of a drug plus-minus on the basis of proved recipe, and combine the treatment measure of doctor trained in Western medicine.Both do not carry out deep research, do not develop new Chinese medicine yet with unique curative effect to disease.
Summary of the invention
To above-mentioned prior art, the invention provides a kind of oral liquid of treating viral myocarditis.
The present invention realizes through following technical scheme:
A kind of oral liquid of treating viral myocarditis is processed by following crude drug: the Radix Astragali 25～35 grams, Radix Sophorae Flavescentis 25～35 grams; Rhizoma Coptidis 25～35 grams, Os Draconis 15～25 grams, Semen Ziziphi Spinosae 15～25 grams; The Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 15～25 grams, Flos Lonicerae 15～25 grams, Radix Angelicae Sinensis 5～15 grams; Rhizoma Polygoni Cuspidati 5～15 grams, Radix Glycyrrhizae Preparata 5～15 grams.
Preferably, process: the Radix Astragali 30 grams, Radix Sophorae Flavescentis 30 grams, Rhizoma Coptidis 30 grams, Os Draconis 20 grams, Semen Ziziphi Spinosae 20 grams, the Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 20 grams, Flos Lonicerae 20 grams, Radix Angelicae Sinensis 10 grams, Rhizoma Polygoni Cuspidati 10 grams, Radix Glycyrrhizae Preparata 10 grams by following crude drug.
Preferably, process: the Radix Astragali 28 grams, Radix Sophorae Flavescentis 33 grams, Rhizoma Coptidis 28 grams, Os Draconis 23 grams, Semen Ziziphi Spinosae 18 grams, the Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 18 grams, Flos Lonicerae 23 grams, Radix Angelicae Sinensis 8 grams, Rhizoma Polygoni Cuspidati 12 grams, Radix Glycyrrhizae Preparata 8 grams by following crude drug.
Preferably, process: the Radix Astragali 32 grams, Radix Sophorae Flavescentis 28 grams, Rhizoma Coptidis 32 grams, Os Draconis 18 grams, Semen Ziziphi Spinosae 22 grams, the Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 22 grams, Flos Lonicerae 18 grams, Radix Angelicae Sinensis 12 grams, Rhizoma Polygoni Cuspidati 8 grams, Radix Glycyrrhizae Preparata 12 grams by following crude drug.
The method for preparing of the oral liquid of said treatment viral myocarditis is: get each crude drug, mix decocte with water 1～2 hour; Cross and filter filtrating; Decocte with water 0.5～1.5 hour again in the filtering residue is crossed and is filtered filtrating, merges filtrating twice; Being concentrated into relative density is 1.22～1.24 (50 ℃), promptly gets.
The oral liquid of treatment viral myocarditis of the present invention has curative effect preferably to viral myocarditis, and is oral during treatment, every day twice, one after each meal.Can cure in general 20～30 days.The oral liquid of treatment viral myocarditis of the present invention, evident in efficacy, and instant effect, having no side effect, total effective rate reaches 97.3%.
The specific embodiment
Below in conjunction with embodiment the present invention is further described.
The oral liquid of embodiment 1 preparation treatment viral myocarditis
Prescription is: the Radix Astragali 30 grams, Radix Sophorae Flavescentis 30 grams, Rhizoma Coptidis 30 grams, Os Draconis 20 grams, Semen Ziziphi Spinosae 20 grams, the Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 20 grams, Flos Lonicerae 20 grams, Radix Angelicae Sinensis 10 grams, Rhizoma Polygoni Cuspidati 10 grams, Radix Glycyrrhizae Preparata 10 grams (potion).
Method for preparing is: get each crude drug, mix decocte with water 1.5 hours; Cross and filter filtrating, decocte with water 1 hour again in the filtering residue is crossed and is filtered filtrating; Merge filtrating twice, being concentrated into relative density is 1.22～1.24 (50 ℃), promptly gets the oral liquid of treating viral myocarditis.
The oral liquid of embodiment 2 preparation treatment viral myocarditis
Prescription is: the Radix Astragali 28 grams, Radix Sophorae Flavescentis 33 grams, Rhizoma Coptidis 28 grams, Os Draconis 23 grams, Semen Ziziphi Spinosae 18 grams, the Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 18 grams, Flos Lonicerae 23 grams, Radix Angelicae Sinensis 8 grams, Rhizoma Polygoni Cuspidati 12 grams, Radix Glycyrrhizae Preparata 8 grams.
Method for preparing is: get each crude drug, mix, decocte with water 1.5 hours is crossed and is filtered filtrating, and decocte with water 1 hour is again crossed and filtered filtrating in the filtering residue, merges filtrating twice, and being concentrated into relative density is 1.22～1.24 (50 ℃), promptly gets.
The oral liquid of embodiment 3 preparation treatment viral myocarditis
Prescription is: the Radix Astragali 32 grams, Radix Sophorae Flavescentis 28 grams, Rhizoma Coptidis 32 grams, Os Draconis 18 grams, Semen Ziziphi Spinosae 22 grams, the Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 22 grams, Flos Lonicerae 18 grams, Radix Angelicae Sinensis 12 grams, Rhizoma Polygoni Cuspidati 8 grams, Radix Glycyrrhizae Preparata 12 grams.
Method for preparing is: get each crude drug, mix, decocte with water 1.5 hours is crossed and is filtered filtrating, and decocte with water 1 hour is again crossed and filtered filtrating in the filtering residue, merges filtrating twice, and being concentrated into relative density is 1.22～1.24 (50 ℃), promptly gets.
The oral liquid of embodiment 4 preparation treatment viral myocarditis
Prescription is: the Radix Astragali 25 grams, Radix Sophorae Flavescentis 35 grams, Rhizoma Coptidis 25 grams, Os Draconis 25 grams, Semen Ziziphi Spinosae 15 grams, the Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 25 grams, Flos Lonicerae 15 grams, Radix Angelicae Sinensis 15 grams, Rhizoma Polygoni Cuspidati 5 grams, Radix Glycyrrhizae Preparata 15 grams.
Method for preparing is: get each crude drug, mix, decocte with water 1 hour is crossed and is filtered filtrating, and decocte with water 0.5 hour is again crossed and filtered filtrating in the filtering residue, merges filtrating twice, and being concentrated into relative density is 1.22～1.24 (50 ℃), promptly gets.
The oral liquid of embodiment 5 preparation treatment viral myocarditis
Prescription is: the Radix Astragali 35 grams, Radix Sophorae Flavescentis 25 grams, Rhizoma Coptidis 35 grams, Os Draconis 15 grams, Semen Ziziphi Spinosae 25 grams, the Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 15 grams, Flos Lonicerae 25 grams, Radix Angelicae Sinensis 5 grams, Rhizoma Polygoni Cuspidati 15 grams, Radix Glycyrrhizae Preparata 5 grams.
Method for preparing is: get each crude drug, mix, decocte with water 2 hours is crossed and is filtered filtrating, and decocte with water 1.5 hours is again crossed and filtered filtrating in the filtering residue, merges filtrating twice, and being concentrated into relative density is 1.22～1.24 (50 ℃), promptly gets.
Clinical data:
Physical data: viral myocarditis patient 217 examples, random packet.110 examples are organized in treatment: male 72 examples, women 38 examples, 20～53 years old age.Matched group 107 examples: male 70 examples, women 37 examples, 20～52 years old age.Two groups of case sexes, age, pathogenic factor and clinical diagnosises have comparability through statistical procedures there are no significant difference.
Diagnostic criteria: " adult's acute viral myocarditis diagnosis reference standard " (draft) according to nineteen ninety-five whole nation myocarditis cardiomyopathy symposium proposes made a definite diagnosis.
Therapeutic Method: two groups of cases are after being admitted to hospital, all to sub-general treatment: bed rest, high egg are from, homovitamin and light diet, interferon alpha-2 ten thousand U intramuscular injections, every day 1 time.The matched group employing adds the magnesium polarized solution, and (25% magnesium sulfate 10ml adds quiet of 10% glucose 500ml for 10% potassium chloride 10ml, insulin 12U, once a day) treatment.The treatment group adopts oral liquid (the embodiment 1 preparation) treatment of treatment viral myocarditis of the present invention, and every day, potion was taken at twice, one after each meal.
Criterion of therapeutical effect:
Cure: symptom, signs such as uncomfortable in chest, cardiopalmus and pareordia dull pain disappear, and it is normal that serum zymetology (CKLDH) inspection recovers fully, and Electrocardioscopy T ripple, sT section and abnormality Q wave recover normal basically.
Produce effects: clinical symptoms, sign obviously alleviate, and Serological testing recovers normally basically, and Electrocardioscopy T ripple and ST section are than being clearly better before treating or recovering normal basically.
Effectively: symptom, sign alleviate before the treatment to some extent, and the serum enzyme labeled compound assay before is clearly better, and Electrocardioscopy T ripple and ST section and abnormality Q wave make moderate progress when falling ill.
Invalid: clinical symptoms, sign, serum enzyme labeled compound assay and Electrocardioscopy all do not have improvement.
Therapeutic outcome: treat after 25 days, observe the curative effect, as shown in table 1.
| Total routine number | Cure | Produce effects | Effectively | Invalid | Total effective rate | |
| Matched group | 107 | 47 | 26 | 26 | 8 | 92.5% |
| The treatment group | 110 | 63 | 29 | 15 | 3 | 97.3% |
Case 1 Zheng, the man, 28 years old, the fatigue one day symptoms such as cardiopalmus, pale complexion, pain uncomfortable in chest, perspiration occurred after taking off power, was diagnosed as viral myocarditis after being sent to hospital; Adopt medicine of the present invention to treat (embodiment 1 preparation), every day, potion was taken at twice, one after each meal, simultaneously; Cooperate common treatment (vitamin C, Interferon Muscular Injection), after 20 days, transference cure; Recovery from illness continues to take and consolidated curative effect in 10 days, pays a return visit after 6 months, does not see recurrence.
Case 2 fields so-and-so, woman, 32 years old, ill viral myocarditis, cardiopalmus, arrhythmia; Pareordia is felt oppressed, and perspires, and breathes hard, and adopts medicine of the present invention to treat (embodiment 1 preparation), and every day, potion was taken at twice; One after each meal simultaneously, cooperates common treatment (vitamin C, Interferon Muscular Injection), after 25 days; Transference cure, recovery from illness continues to take and consolidated curative effect in 15 days, pays a return visit after 6 months, does not see recurrence.
Claims (5)
1. an oral liquid of treating viral myocarditis is characterized in that: processed by following crude drug: the Radix Astragali 25～35 grams, Radix Sophorae Flavescentis 25～35 grams; Rhizoma Coptidis 25～35 grams, Os Draconis 15～25 grams, Semen Ziziphi Spinosae 15～25 grams; The Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 15～25 grams, Flos Lonicerae 15～25 grams, Radix Angelicae Sinensis 5～15 grams; Rhizoma Polygoni Cuspidati 5～15 grams, Radix Glycyrrhizae Preparata 5～15 grams.
2. a kind of oral liquid of treating viral myocarditis according to claim 1 is characterized in that: processed by following crude drug: the Radix Astragali 30 grams, Radix Sophorae Flavescentis 30 grams; Rhizoma Coptidis 30 grams, Os Draconis 20 grams, Semen Ziziphi Spinosae 20 grams; The Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 20 grams, Flos Lonicerae 20 grams, Radix Angelicae Sinensis 10 grams; Rhizoma Polygoni Cuspidati 10 grams, Radix Glycyrrhizae Preparata 10 grams.
3. a kind of oral liquid of treating viral myocarditis according to claim 1 is characterized in that: processed by following crude drug: the Radix Astragali 28 grams, Radix Sophorae Flavescentis 33 grams; Rhizoma Coptidis 28 grams, Os Draconis 23 grams, Semen Ziziphi Spinosae 18 grams; The Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 18 grams, Flos Lonicerae 23 grams, Radix Angelicae Sinensis 8 grams; Rhizoma Polygoni Cuspidati 12 grams, Radix Glycyrrhizae Preparata 8 grams.
4. a kind of oral liquid of treating viral myocarditis according to claim 1 is characterized in that: processed by following crude drug: the Radix Astragali 32 grams, Radix Sophorae Flavescentis 28 grams; Rhizoma Coptidis 32 grams, Os Draconis 18 grams, Semen Ziziphi Spinosae 22 grams; The Clinopodium Polycephalum Herba Clinopodii (Herba Clinopodii Polycephali) 22 grams, Flos Lonicerae 18 grams, Radix Angelicae Sinensis 12 grams; Rhizoma Polygoni Cuspidati 8 grams, Radix Glycyrrhizae Preparata 12 grams.
5. the described a kind of method for preparing of treating the oral liquid of viral myocarditis of claim 1 is characterized in that: get each crude drug, mix; Decocte with water 1～2 hour is crossed and to be filtered filtrating, decocte with water 0.5～1.5 hour again in the filtering residue; Cross and filter filtrating; Merge filtrating twice, being concentrated into relative density is 1.22～1.24 (50 ℃), promptly gets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210247324.6A CN102727605B (en) | 2012-07-17 | 2012-07-17 | Oral liquid for treating vital myocarditis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210247324.6A CN102727605B (en) | 2012-07-17 | 2012-07-17 | Oral liquid for treating vital myocarditis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102727605A true CN102727605A (en) | 2012-10-17 |
| CN102727605B CN102727605B (en) | 2014-03-05 |
Family
ID=46984369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210247324.6A Expired - Fee Related CN102727605B (en) | 2012-07-17 | 2012-07-17 | Oral liquid for treating vital myocarditis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727605B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547701A (en) * | 2015-01-09 | 2015-04-29 | 卢红 | Compound preparation for treatment of myocarditis and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708290A (en) * | 2009-12-18 | 2010-05-19 | 河北惟祥福中药科技开发有限公司 | Chinese medicinal preparation for treating viral myocarditis |
| CN102160884A (en) * | 2010-02-24 | 2011-08-24 | 吕凌燕 | Chinese medicinal preparation for treating acute period vital myocarditis |
-
2012
- 2012-07-17 CN CN201210247324.6A patent/CN102727605B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708290A (en) * | 2009-12-18 | 2010-05-19 | 河北惟祥福中药科技开发有限公司 | Chinese medicinal preparation for treating viral myocarditis |
| CN102160884A (en) * | 2010-02-24 | 2011-08-24 | 吕凌燕 | Chinese medicinal preparation for treating acute period vital myocarditis |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547701A (en) * | 2015-01-09 | 2015-04-29 | 卢红 | Compound preparation for treatment of myocarditis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102727605B (en) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100546620C (en) | A kind of Chinese medicine for the treatment of respiratory tract disease and preparation method thereof | |
| CN104645132A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy, preparation method, traditional Chinese medicine preparation and application of traditional Chinese medicine composition | |
| CN1150928C (en) | Medicine for curing cancers and its preparation method | |
| CN102988469A (en) | Traditional Chinese medicine composition for preventing and treating influenza virus infection as well as preparation method and application thereof | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN103623216A (en) | Traditional Chinese medicinal preparation for treating children's virus myocarditis | |
| CN102847061A (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN102727605B (en) | Oral liquid for treating vital myocarditis | |
| CN104784670A (en) | Pharmaceutical composition for treating myocarditis and preparation method of pharmaceutical composition | |
| CN102671056B (en) | Chinese medicinal composition for treating hepatitis and preparation method thereof | |
| CN103446410B (en) | Traditional Chinese medicine preparation for treating viral myocarditis | |
| CN107837384A (en) | A kind of Chinese medicine composition for treating hand-foot-and-mouth disease | |
| CN101347595B (en) | Chinese medicine for treating rheumatic heart of children | |
| CN102895405A (en) | Oral solution for treatment of viral myocarditis of child | |
| CN104706813A (en) | Mulberry-glossy privet fruit health composition | |
| CN103961562A (en) | Concentrated oral solution for treating recurrent oral ulcer by type of fire excess from yin deficiency | |
| CN102836403B (en) | Chinese medicine for treating chronic nephritis by using root of low greenbrier | |
| CN103301368A (en) | Medicament for treating hyperactivity | |
| CN103768299B (en) | A kind of first aid medicine preparation method treating heatstroke | |
| CN1281223C (en) | Myocarditis treating medicine and its preparing process | |
| CN106074643A (en) | Cortex Acanthopanacis Giraldii leaf and extract purposes in the medicine or health food of preparation resisting fatigue thereof | |
| CN100333769C (en) | Chinese herbal granule for treating viral myocarditis and its preparing process | |
| CN1329050C (en) | Medication of eliminating stagnated food and preparation method | |
| CN104706815A (en) | Wolfberry-pseudo-ginseng health composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140305 Termination date: 20140717 |
|
| EXPY | Termination of patent right or utility model |